{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:22:46Z","timestamp":1791285766191,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ando.2015.10.009","type":"journal-article","created":{"date-parts":[[2015,11,27]],"date-time":"2015-11-27T09:33:49Z","timestamp":1448616829000},"page":"650-657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review"],"prefix":"10.1016","volume":"76","author":[{"given":"Demba","family":"Di\u00e9dhiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cuny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00efd","family":"Norou Diop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Weryha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2015.10.009_bib0255","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.10.009_bib0260","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2015.10.009_bib0265","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ando.2015.10.009_bib0270","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2015.10.009_bib0275","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: Denosumab fracture Intervention Randomized placebo Controlled Trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.10.009_bib0280","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2015.10.009_bib0285","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"36","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2015.10.009_bib0290","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/jbmr.81","article-title":"Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate","volume":"25","author":"Seeman","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0295","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jocd.2008.04.001","article-title":"Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate","volume":"11","author":"Beck","year":"2008","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.ando.2015.10.009_bib0300","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0305","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ando.2015.10.009_bib0310","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1210\/jc.2013-1402","article-title":"Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial","volume":"98","author":"Anastasilakis","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.10.009_bib0315","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy. A randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ando.2015.10.009_bib0320","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women sub optimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.ando.2015.10.009_bib0325","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2015.10.009_bib0330","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.10.009_bib0335","first-page":"1953","volume":"25","author":"Brown","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ando.2015.10.009_bib0340","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00198-011-1786-8","article-title":"Dose\u2013response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis","volume":"23","author":"Nakamura","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ando.2015.10.009_bib0345","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled Study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0350","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.bone.2011.08.007","article-title":"A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women","volume":"49","author":"Kumagai","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ando.2015.10.009_bib0355","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.10.009_bib0360","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","article-title":"Differing effects of denosumab and alendronate on cortical and trabecular bone","volume":"59","author":"Zebaze","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.ando.2015.10.009_bib0365","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","article-title":"Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures","volume":"27","author":"Austin","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0370","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/GME.0b013e318267f909","article-title":"Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture","volume":"20","author":"Simon","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.ando.2015.10.009_bib0375","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0380","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.10.009_bib0385","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jbmr.536","article-title":"Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis","volume":"27","author":"McClung","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0390","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0395","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/jc.2010-2784","article-title":"Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk","volume":"96","author":"Boonen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.10.009_bib0400","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/jbmr.1606","article-title":"Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX","volume":"27","author":"McCloskey","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0405","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0410","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trials","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.ando.2015.10.009_bib0415","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year. Results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.10.009_bib0420","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jocd.2012.02.006","article-title":"Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM Study","volume":"16","author":"Bolognese","year":"2013","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.ando.2015.10.009_bib0425","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00198-012-2052-4","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial","volume":"24","author":"McClung","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ando.2015.10.009_bib0430","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/jbmr.1681","article-title":"Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab","volume":"27","author":"Gatti","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0435","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0440","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2010.04.594","article-title":"Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density","volume":"47","author":"Genant","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.ando.2015.10.009_bib0445","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bone.2013.07.011","article-title":"Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab","volume":"56","author":"Genant","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.ando.2015.10.009_bib0450","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jbmr.2024","article-title":"Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab","volume":"29","author":"Keaveny","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0455","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0460","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.10.009_bib0465","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0470","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1002\/jbmr.492","article-title":"Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer","volume":"26","author":"Smith","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2015.10.009_bib0475","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ando.2015.10.009_bib0480","first-page":"2113","article-title":"Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis","volume":"7","author":"Zhou","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.ando.2015.10.009_bib0485","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2013-3795","article-title":"Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response based meta-analysis","volume":"99","author":"Mandema","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.10.009_bib0490","first-page":"1","article-title":"Compliance and treatment satisfaction of post-menopausal women treated for osteoporosis. Compliance with osteoporosis treatment","volume":"10","author":"Huas","year":"2010","journal-title":"BMC Woman Health"},{"key":"10.1016\/j.ando.2015.10.009_bib0495","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2015.10.009_bib0500","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jbspin.2012.02.014","article-title":"2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis","volume":"79","author":"Briota","year":"2012","journal-title":"Joint Bone Spine"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426615011117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426615011117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:48:20Z","timestamp":1757717300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426615011117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0003426615011117"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2015.10.009","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2015.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}